JOHN WENCESLAO: Open Payments
NPI 1740203868 · BLOOMFIELD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,690 in 170 payments from 34 companies in 2025. Trend: 2023 $4,062 · 2024 $3,917 · 2025 $3,690
Food & beverage: $3,591Education: $100
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $448 |
| AstraZeneca Pharmaceuticals LP | 16 | $421 |
| GlaxoSmithKline, LLC. | 14 | $294 |
| Esperion Therapeutics, Inc. | 10 | $193 |
| Novartis Pharmaceuticals Corporation | 6 | $176 |
| Ardelyx, Inc. | 8 | $171 |
| Exact Sciences Corporation | 8 | $163 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $137 |
| E.R. Squibb & Sons, L.L.C. | 7 | $137 |
| Actelion Pharmaceuticals US, Inc. | 3 | $135 |
Products named: AIRSUPRA, TRELEGY ELLIPTA, NEXLETOL, IBSRELA, LEQVIO, UBRELVY, VRAYLAR, XIFAXAN.
Industry payments across CT — which companies pay providers there.
